Heiske Group has strong technical force, a professional scientific research team with solid theoretical foundation, rich experience and outstanding innovation ability, and an independent R&D building and pilot plant. Up to now, R&D Center has developed 22 new drugs (including products with technology transfer) for the company, which are widely used in parenteral nutrition, anti-infection, digestive system, nervous system and other fields. Among them, invert sugar injection, sodium fusidate for injection, polyene phosphatidylcholine injection and fat-soluble vitamins for injection have been included in the national medical insurance catalogue, covering more than 70% of the third-class first-class hospitals in China, and
Heiske Group has a perfect sales network and mature marketing channels. At present, the group's marketing network has covered all provinces and cities in China, and has established long-term and stable strategic partnerships with more than 0/000 professional pharmaceutical sales companies nationwide. In just a few years, Hesko has experienced a leap-forward development, with an annual sales income of 600 million yuan.
Since its establishment, the group has always adhered to the business philosophy of "market-oriented, with new drug research and development as the core". After 10 years of capital investment and technology accumulation, the company has now obtained 3 invention patent certificates and more than 30 key prescription drugs under development.
Heiske Group has a professional management team composed of excellent professional managers. While ensuring the stable operation of the management of the Group, we will, as always, take serving human health as our responsibility, take the vision of "devoting ourselves to becoming the most advanced professional developer in the medical field" and take the unshakable mission of "letting domestic patients quickly share the latest international medical technology achievements", adhere to the development path of professional innovation and continue to devote ourselves to developing high-quality and high-tech pharmaceutical products and services.